Skip to content

Comparison of the therapeutic effect of Diazepam and Phenobarbital in recurrence of febrile seizure

Comparison of the therapeutic effect of parenteral Phenobarbital and oral Diazepam on recurrency of febrile seizure in hospitalized children- A randomized controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200608047689N2
Enrollment
90
Registered
2021-02-04
Start date
2021-01-27
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile seizure. Febrile convulsions

Interventions

Intervention 1: Intervention group: 1. Intravenous Phenobarbital at a dose of 3 to 5 milligrams per kilogram per day will be divided into two doses that will be administered daily for 3 days at the ti

Sponsors

Rasht University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Months to 6 Years

Inclusion criteria

Inclusion criteria: Parents complete satisfaction with the children's presence in the study Children who experience febrile seizure for the first time

Exclusion criteria

Exclusion criteria: History of any neurological disease Children with previous history of seizure and febrile seizure Imbalance of electrolytes associated with chronic disease

Design outcomes

Primary

MeasureTime frame
Recurrence of febrile seizure. Timepoint: The initial outcome will be measured during three days of hospitalization. Method of measurement: The occurrence of any types of seizure.

Secondary

MeasureTime frame
The side effects of the drugs such as lethargy, rash and irritability. Timepoint: In 3 days during hospitalization. Method of measurement: The occurrence of complications.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Bidabadi

Rasht University of Medical Sciences

bidabadi@mail.com+98 13 3372 9104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026